PLRX Key Statistics, Chart & Performance
The current stock price of PLRX is 1.09 USD. In the past month the price decreased by -19.26%. In the past year, price decreased by -86.01%.
PLRX Technical Analysis
PLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PLRX. The financial health of PLRX is average, but there are quite some concerns on its profitability.
PLRX Financial Highlights
Over the last trailing twelve months PLRX reported a non-GAAP Earnings per Share(EPS) of -2.88. The EPS increased by 13.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.03% | ||
| ROE | -94.04% | ||
| Debt/Equity | 0.14 |
PLRX Forecast & Estimates
12 analysts have analysed PLRX and the average price target is 3.32 USD. This implies a price increase of 204.13% is expected in the next year compared to the current price of 1.09.
PLRX Ownership
PLRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.41 | 1.047T | ||
| JNJ | JOHNSON & JOHNSON | 20.57 | 564.909B | ||
| MRK | MERCK & CO. INC. | 22.13 | 293.697B | ||
| PFE | PFIZER INC | 8.82 | 152.263B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.8 | 117.3B | ||
| ZTS | ZOETIS INC | 18.5 | 55.835B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.5 | 25.214B | ||
| VTRS | VIATRIS INC | 5.68 | 16.539B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.06 | 12.123B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.39 | 9.353B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PLRX
Company Profile
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 171 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Company Info
PLIANT THERAPEUTICS INC
331 Oyster Point Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Bernard Coulie
Employees: 171
Phone: 16504816770
PLIANT THERAPEUTICS INC / PLRX FAQ
What does PLIANT THERAPEUTICS INC do?
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 171 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Can you provide the latest stock price for PLIANT THERAPEUTICS INC?
The current stock price of PLRX is 1.09 USD. The price decreased by -7.23% in the last trading session.
Does PLRX stock pay dividends?
PLRX does not pay a dividend.
How is the ChartMill rating for PLIANT THERAPEUTICS INC?
PLRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists PLRX stock?
PLRX stock is listed on the Nasdaq exchange.
How is the valuation of PLIANT THERAPEUTICS INC (PLRX) based on its PE ratio?
PLIANT THERAPEUTICS INC (PLRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.88).
What is the employee count for PLRX stock?
PLIANT THERAPEUTICS INC (PLRX) currently has 171 employees.